Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (55)

« Back to Publications

Intravenous iron for the treatment of iron deficiency in adults with cystic fibrosis: a prospective observational cohort study.

Talbot NP. et al, (2025), Eur Respir J, 66

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma

HINKS T., (2024), Journal of Allergy and Clinical Immunology

Nanopore sequencing of influenza A and B in Oxfordshire and the United Kingdom, 2022-23.

Cane J. et al, (2024), J Infect, 88

Anti-inflammatory effects of oral prednisolone at stable state in people treated with mepolizumab: a proteomic and bulk transcriptomics analysis

Howell I. et al, (2024)

Nanopore sequencing of influenza A and B in Oxfordshire and the United Kingdom, 2022-23

Cane J. et al, (2023)

Additional effects of oral prednisolone following mepolizumab on the nasal transcriptome

Howell I. et al, (2023), EUROPEAN RESPIRATORY JOURNAL, 62

Identifying Bacterial Airways Infection in Stable Severe Asthma Using Oxford Nanopore Sequencing Technologies

JABEEN MF. et al, (2022), Microbiology Spectrum

Method development for flow-cytometric analysis of primary human airway epithelia infected with non-typeable Haemophilus influenzae

Horton KL. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60

The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells.

Zhuang X. et al, (2021), iScience, 24

The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells.

Zhuang X. et al, (2021), iScience

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

HINKS T. et al, (2021), The Lancet Respiratory Medicine

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.

Ramakrishnan S. et al, (2021), Lancet Respir Med, 9, 763 - 772

A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial

Hinks TSC. et al, (2021)

A Randomised Clinical Trial of Azithromycin Versus Standard Care in Ambulatory COVID-19 – The ATOMIC2 Trial

Hinks TSC. et al, (2021), SSRN Electronic Journal

Inhaled Budesonide in the Treatment of Early COVID-19 Illness: A Randomised Controlled Trial

Ramakrishnan S. et al, (2021)

Load More

Include forthcoming?